Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
140.00    -1.25 (-0.88%)
Bid:
137.00
Ask:
144.50
Spread: 7.50 (5.474%)
Market Cap: £109.86m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Systems integration partner

13 May 2005 07:01

Xaar PLC13 May 2005 FOR IMMEDIATE RELEASE 13 May 2005 Xaar plc IMPIKA APPOINTED AS SYSTEMS INTEGRATION PARTNER Xaar plc ("Xaar"), the inkjet printing technology group headquartered inCambridge, and IMPIKA SA ("IMPIKA") of Aubagne, France are pleased to announce ajoint agreement for the provision of integration services for Xaar printheadsand other products. Under the agreement both parties will co-operate to provide complete turnkeysolutions for clients wishing to use Xaar technology for their productionprocesses, to open up new applications and create bespoke solutions. IMPIKA haslong experience with inkjet, including its application to the printing ofplastic and smart cards, packaging, labelling as well as special applicationsfor printing on CDs, glass and metal. Impika is also developing solutions basedon its material jetting technology for microelectronics and biomedicalapplications. Nigel Berry, Deputy CEO of Xaar commented: "I am very pleased to announce thisrelationship with IMPIKA. We previously stated our intention to partner with asmall number of high quality integrators which can offer existing and potentialusers of our technology a complete package of integration skills and bespokeequipment. We have known the team at IMPIKA for some time now and have beenimpressed by their standards and innovation. I look forward to working withthem on future projects." Paul Morgavi, IMPIKA'S CEO said: "Xaar is a great partner for us and we arealready forming strong links with their technical and marketing teams. There isa clear synergy between Xaar and Impika with both parties introducing newmarkets into the joint relationship. Last year we introduced our C9000 productbased on Xaar's Leopard printhead and we are working on various projects foradapting our IPS print engine to the next generation of Xaar printheads, likethe Omnidot and HSS. Full commercial release of these products is anticipatedlater this year or early next year." About Xaar Xaar plc is a market-leading inkjet technology company. It targets the world'sindustrial, commercial and office printing markets. The industrial andcommercial printing markets are targeted by Xaar's own range of inkjet productsin conjunction with partners and other key players in those markets; the officeprinting market is approached through Xaar's strong list of licensees.Additional information about Xaar is available at www.xaar.co.uk. About IMPIKA: Created in March 2003 as a spin-out from Gemplus, IMPIKA is headquartered atAubagne in the south of France. IMPIKA offers high-performance industrialprinting and material jetting solutions using inkjet technology; it currentlyhas 37 employees. IMPIKA designs, develops, implements and markets hardware and softwaresolutions, as well as the required engineering as regards ink and materialjetting, for industrial applications including digital printing,microelectronics and biotechnologies. Additional information about IMPIKA isavailable at www.impika.com. Contacts Xaar plc: 01223-423663Ian Dinwoodie, Chief Executive www.xaar.co.ukNigel Berry, Group Finance Director & Deputy Chief Executive IMPIKA: +33 (0)4 42 62 43 00Paul Morgavi, CEO www.impika.com Bankside Consultants:Steve Liebmann 020-7444-4163 /07802-888159 This information is provided by RNS The company news service from the London Stock Exchange
Date   Source Headline
26th Apr 20215:51 pmRNSHolding(s) in Company
22nd Apr 202112:18 pmRNSDirector Declaration
15th Apr 20212:24 pmRNSNotice of 2020 Preliminary Results
6th Apr 202112:12 pmRNSHolding(s) in Company
1st Apr 20211:50 pmRNSTotal Voting Rights
1st Mar 20215:18 pmRNSTotal Voting Rights
10th Feb 20212:25 pmRNSHolding(s) in Company
1st Feb 202111:01 amRNSTotal Voting Rights
28th Jan 20212:49 pmRNSHolding(s) in Company
21st Jan 202110:27 amRNSHolding(s) in Company
14th Jan 20217:00 amRNSTrading Statement
4th Jan 202111:38 amRNSTotal Voting Rights
1st Dec 20204:43 pmRNSTotal Voting Rights
9th Nov 202010:42 amRNSHolding(s) in Company
4th Nov 202011:00 amRNSUpdate on cyber security incident
3rd Nov 202011:29 amRNSGrant of options under SAYE Scheme
3rd Nov 202011:15 amRNSHolding(s) in Company
2nd Nov 202011:40 amRNSTotal Voting Rights
7th Oct 20207:00 amRNSNotice of cyber security incident
6th Oct 20204:48 pmRNSHolding(s) in Company
1st Oct 202012:59 pmRNSTotal Voting Rights
30th Sep 20207:00 amRNS2020 Interim Results
3rd Sep 20204:24 pmRNSHolding(s) in Company
3rd Sep 20201:20 pmRNSNotice of Interim Results
1st Sep 202010:42 amRNSTotal Voting Rights
5th Aug 202012:47 pmRNSTotal Voting Rights
3rd Aug 20208:59 amRNSChange of Adviser
16th Jul 20207:00 amRNSTrading Statement
9th Jul 20204:36 pmRNSPrice Monitoring Extension
1st Jul 20203:17 pmRNSConfirmation of Board Change & Succession
1st Jul 202011:47 amRNSTotal Voting Rights
5th Jun 20207:00 amRNSGrant of Options
2nd Jun 202011:16 amRNSTotal Voting Rights
2nd Jun 202011:13 amRNSResult of AGM
2nd Jun 20207:00 amRNSTrading Statement
15th May 202010:59 amRNSHolding(s) in Company
7th May 20207:00 amRNSNotice of Annual General Meeting
1st May 20203:10 pmRNSTotal Voting Rights
30th Apr 20202:27 pmRNSHolding(s) in Company
29th Apr 202012:04 pmRNSDisclosure of Rights attached to Equity Shares
29th Apr 202011:41 amRNSGrant of option
28th Apr 20205:27 pmRNSHolding(s) in Company
27th Apr 20202:23 pmRNSHolding(s) in Company
27th Apr 20202:00 pmRNSDirectorate Change - Appointment
24th Apr 20203:10 pmRNSHolding(s) in Company
24th Apr 20203:02 pmRNSAnnual Financial Report
23rd Apr 20202:35 pmRNSDirector/PDMR Shareholding
23rd Apr 20207:00 amRNSAnnual Financial Report
9th Apr 20209:15 amRNSHolding(s) in Company
6th Apr 20203:35 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.